BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 20118510)

  • 1. [Bone and Men's Health. Effects of aromatase inhibitors on human osteoblasts].
    Sasano H; Miki Y
    Clin Calcium; 2010 Feb; 20(2):189-97. PubMed ID: 20118510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aromatase inhibitor-associated arthralgia syndrome.
    Burstein HJ
    Breast; 2007 Jun; 16(3):223-34. PubMed ID: 17368903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line.
    Sonne-Hansen K; Lykkesfeldt AE
    J Steroid Biochem Mol Biol; 2005 Jan; 93(1):25-34. PubMed ID: 15748829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?
    Miller WR; Bartlett J; Brodie AM; Brueggemeier RW; di Salle E; Lønning PE; Llombart A; Maass N; Maudelonde T; Sasano H; Goss PE
    Oncologist; 2008 Aug; 13(8):829-37. PubMed ID: 18695261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: a possible androgenic bone protective effects induced by exemestane.
    Miki Y; Suzuki T; Hatori M; Igarashi K; Aisaki KI; Kanno J; Nakamura Y; Uzuki M; Sawai T; Sasano H
    Bone; 2007 Apr; 40(4):876-87. PubMed ID: 17254854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular and molecular effects of growth hormone and estrogen on human bone cells.
    Kassem M
    APMIS Suppl; 1997; 71():1-30. PubMed ID: 9357492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aromatase in the context of breast and endometrial cancer. A review.
    Jongen VH; Hollema H; Van Der Zee AG; Heineman MJ
    Minerva Endocrinol; 2006 Mar; 31(1):47-60. PubMed ID: 16498363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aromatase inhibitor and bone.
    Miki Y; Suzuki T; Sasano H
    Biomed Pharmacother; 2007 Oct; 61(9):540-2. PubMed ID: 17904790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In situ estrogen production and its regulation in human breast carcinoma: from endocrinology to intracrinology.
    Sasano H; Miki Y; Nagasaki S; Suzuki T
    Pathol Int; 2009 Nov; 59(11):777-89. PubMed ID: 19883428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of aromatase inhibitors on bone metabolism.
    Folkestad L; Bjarnason NH; Bjerregaard JK; Brixen K
    Basic Clin Pharmacol Toxicol; 2009 Jan; 104(1):3-10. PubMed ID: 19152547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aromatase inhibitors and breast cancer.
    Miller WR
    Minerva Endocrinol; 2006 Mar; 31(1):27-46. PubMed ID: 16498362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are all aromatase inhibitors the same? A review of the current evidence.
    Jänicke F
    Breast; 2004 Dec; 13 Suppl 1():S10-8. PubMed ID: 15585378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
    McCaig FM; Renshaw L; Williams L; Young O; Murray J; Macaskill EJ; McHugh M; Hannon R; Dixon JM
    Breast Cancer Res Treat; 2010 Feb; 119(3):643-51. PubMed ID: 19941160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant aromatase inhibitors and bone health.
    Chowdhury S; Pickering LM; Ellis PA
    J Br Menopause Soc; 2006 Sep; 12(3):97-103. PubMed ID: 16953982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of third-generation aromatase inhibitors on bone.
    McCloskey E
    Eur J Cancer; 2006 May; 42(8):1044-51. PubMed ID: 16554149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focus on anastrozole and breast cancer.
    Mokbel K
    Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective.
    Garreau JR; Delamelena T; Walts D; Karamlou K; Johnson N
    Am J Surg; 2006 Oct; 192(4):496-8. PubMed ID: 16978958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
    Winer EP; Hudis C; Burstein HJ; Wolff AC; Pritchard KI; Ingle JN; Chlebowski RT; Gelber R; Edge SB; Gralow J; Cobleigh MA; Mamounas EP; Goldstein LJ; Whelan TJ; Powles TJ; Bryant J; Perkins C; Perotti J; Braun S; Langer AS; Browman GP; Somerfield MR
    J Clin Oncol; 2005 Jan; 23(3):619-29. PubMed ID: 15545664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.